News | July 17, 2014

Focal Healthcare to Develop New Targeted Prostate Biopsy, Therapy Devices

Michael McGuire, M.D., chief of urology at NorthShore University Health System in Chicago, is an early adopter of MRI fusion targeted biopsy and sits on the Clinical Advisory Board of Focal Healthcare.

July 17, 2014 — Focal Healthcare was founded as a spin-off company out of the Centre for Imaging Technology Commercialization (CIMTEC). Focal is developing and marketing MRI (magnetic resonance imaging)-ultrasound fusion biopsy and therapy systems that have strong potential to become the new gold standard in prostate care by capitalizing on CIMTEC's intellectual property, as well as its extensive technology development and commercialization expertise in the medical imaging field.

The current paradigm for prostate cancer care has remained unchanged for more than 25 years. It is well accepted that prostate cancer is fundamentally over-treated either through irradiating or surgically removing the entire prostate; both options include significant risk for life-altering side effects. This is due to the inherent limitations of ultrasound image quality, which is currently used to guide urologists in extracting random biopsy samples from the prostate. Oftentimes, this method leads to the detection of insignificant cancers or the misdiagnosis of serious cancers.

Michael McGuire, chief of urology at NorthShore University Health System in Chicago believes strongly in Focal Healthcare's products and is one of three highly respected experts in the prostate world who sits on its Clinical Advisory Board.

"I am pleased to be able to play a role in the success of Focal's game-changing prostate therapy products by testing the equipment and providing valuable feedback," McGuire said. "The superior capabilities of their products will enable urologists to accurately record biopsy locations for active surveillance of prostate cancer, as well as allow us to appropriately administer therapy, which will significantly reduce the incidence of over-treatment and improve quality of life for our patients."

Focal Healthcare has several patents, a management and development team with more than 30 years of experience in the prostate imaging and clinical device development space, access to validated underlying science and products with portability, cost effectiveness and ease of use.

Related Content

Exact Imaging Becomes UroGPO Imaging Partner
News | Ultrasound Imaging | August 10, 2018
Exact Imaging announced that it has become a UroGPO Imaging Partner, joining the North American urology-specific group...
SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
New Studies Highlight MRI Use for Prostate Cancer Screening and Management
News | Magnetic Resonance Imaging (MRI) | May 21, 2018
Three new studies presented at the 113th annual meeting of the American Urological Association (AUA) highlight the...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Overlay Init